# CGTlive®

> CGTlive® - Healthcare Publication

- Base URL: https://www.cgtlive.com
- Generated: 2026-07-05T16:01:04.697Z
- Content updates: multiple times daily

## Content Access for AI Agents

This site supports content negotiation for AI/LLM consumption. Request any article URL with an appropriate Accept header to receive structured content instead of HTML.

**Supported content types:**
- `text/markdown` — Clean Markdown with YAML frontmatter
- `text/plain` — Plain text (same as Markdown)
- `text/html` — Default HTML response

**Example request:**
```
curl -H "Accept: text/markdown" https://www.cgtlive.com/view/article-slug
```

**YAML frontmatter schema** (returned with every Markdown response):

| Field | Type | Description |
|-------|------|-------------|
| `title` | string | Article headline |
| `description` | string | Summary/excerpt (max 300 chars) |
| `url` | string | Canonical article URL |
| `canonical_url` | string | Canonical URL if different from `url` |
| `published` | ISO 8601 | Original publication date |
| `modified` | ISO 8601 | Last modification date |
| `authors` | string[] | Author display names |
| `content_type` | string | Content category (e.g., "News", "Clinical") |
| `categories` | string[] | Taxonomy categories |
| `tags` | string[] | SEO tags |
| `image` | string | Featured image URL |
| `publisher` | string | Publication/site name |

**Discovery headers** (included on all responses):
- `Link: <https://www.cgtlive.com/llms.txt>; rel="llms"` — RFC 8288 link to this file
- `X-Llms-Txt: https://www.cgtlive.com/llms.txt` — Explicit discovery header

## Usage Policy

- Robots policy: [https://www.cgtlive.com/robots.txt](https://www.cgtlive.com/robots.txt)
- Cache behavior: responses are cached for ~5 minutes (max-age=300, stale-while-revalidate=329)
- Rate guidance: prefer RSS and sitemap feeds over crawling individual pages
- Attribution: All content © MJH Life Sciences. Include source URLs when citing.

## Content Categories

- [Clinical Trials in Progress](https://www.cgtlive.com/clinical-trials-progress)
- [Conferences](https://www.cgtlive.com/conferences)
- [ImmunoLogic](https://www.cgtlive.com/immunologic)
- [News](https://www.cgtlive.com/news)
- [Rapid Readouts](https://www.cgtlive.com/rapid-readouts)
- [Sponsored](https://www.cgtlive.com/sponsored)
- [Topic](https://www.cgtlive.com/topic)
- [Videos](https://www.cgtlive.com/videos)

## Featured Content

- [FDA Approves Tregzi for Matched Donor HSCT in Hematologic Malignancies](https://www.cgtlive.com/view/fda-approves-tregzi-matched-donor-hsct-hematologic-malignancies): The FDA approved Tregzi as the first allogeneic regulatory T cell-based immunotherapy based on Precision-T phase 3 data showing a significant 1-year c...
- [Around the Helix: Cell and Gene Therapy Company Updates – May 27, 2026](https://www.cgtlive.com/view/around-the-helix-cell-and-gene-therapy-company-updates-may-27-2026): Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies. 
- [Guess the Therapy Answer May 22, 2026](https://www.cgtlive.com/view/guess-the-therapy-answer-may-22-2026)
- [Evaluating Miv-Cel for Stiff Person Syndrome](https://www.cgtlive.com/view/evaluating-car-t-miv-cel-stiff-person-syndrome): Amanda Piquet, MD, FAAN, discussed phase 2 data from a trial evaluating the CAR-T therapy mivocabtagene autoleucel for the treatment of stiff person s...
- [Around the Helix: Cell and Gene Therapy Company Updates – May 20, 2026](https://www.cgtlive.com/view/around-the-helix-cell-and-gene-therapy-company-updates-may-20-2026): Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies. 
- [Phase 3 HOPE-3 Data Reinforce Skeletal and Cardiac Benefits of Deramiocel in Duchenne Muscular Dystrophy](https://www.cgtlive.com/view/phase-3-hope-3-data-reinforce-skeletal-cardiac-benefits-deramiocel-in-duchenne-muscular-dystrophy): Phase 3 HOPE-3 data further support deramiocel’s potential to preserve both skeletal and cardiac function in Duchenne muscular dystrophy while slowing...
- [Assessing Miv-Cel for Myasthenia Gravis ](https://www.cgtlive.com/view/assessing-miv-cel-myasthenia-gravis): Srikanth Muppidi, MD, spoke about data from the KYSA-6 trial evaluating Kyverna's CAR-T mivocabtagene autoleucel in MG.
- [Guess the Therapy Answer May 15, 2026](https://www.cgtlive.com/view/guess-the-therapy-answer-may-15-2026)
- [ASGCT 2026: GS-100 Gene Therapy Demonstrates Early Activity in NGLY1 Deficiency](https://www.cgtlive.com/view/asgct-2026-gs-100-gene-therapy-demonstrates-early-activity-ngly1-deficiency): New interim ASGCT 2026 findings suggest investigational AAV9 gene therapy GS-100 may improve motor and cognitive outcomes in children with NGLY1 Defic...
- [ETX101 Gene Therapy Shows Early Developmental, Seizure Benefits in Dravet Syndrome](https://www.cgtlive.com/view/etx101-gene-therapy-shows-early-developmental-seizure-benefits-dravet-syndrome): New ASGCT 2026 data suggest Encoded Therapeutics’ investigational gene therapy ETX101 may meaningfully reduce seizures and alter developmental traject...

## Feeds and Indexes

- [RSS Feed](https://www.cgtlive.com/rss.xml): Latest articles in XML syndication format
- [Sitemap](https://www.cgtlive.com/sitemap.xml): Complete URL index for all published pages
- [News Sitemap](https://www.cgtlive.com/sitemap-news.xml): Recent articles optimized for news indexing
- [Authors Directory](https://www.cgtlive.com/authors): Browse all contributors and their published work